Year 2023

Dr. Pawel Kania

Senior Technical Sales Specialist CEE, NanoTemper Technologies GmbH

Introduction to NanoTemper’s Isothermal Spectral Shift for biophysical characterization of challenging molecular interactions 

07.06.2023 o 14:00

Where:    Institute of Molecular Biology, Slovak Academy of Sciences

Abstract: 

The foundation of NanoTemper Technologies is microscale thermophoresis (MST), a powerful technique to quantify biomolecular interactions. MST is a biophysical technique that measures the strength of the interaction between two molecules by detecting variations in fluorescence signal as a result of an IR-laser induced temperature change. One of NTT’s newest solutions for binding affinity study is isothermal spectral shift technology - when a target is labelled with a fluorophore it generates a particular emission spectrum, and if a ligand binds to this labelled target, the fluorophore’s chemical environment is changed, causing a shift in fluorescence spectra. Thus, these techniques are highly sensitive to virtually any change in molecular properties, allowing for a precise quantification of molecular events independent of the size or nature of the investigated specimen. Along, MST & Isothermal spectral shift detection with their unique capabilities enables researchers to work with the most challenging interactions, directly in their close to native conditions, such as cell or tissue lysate and membrane fraction as well.

 

 

Minulé udalosti spojené s projektom:

Rok 2022

Záverečné stretnutie (Closing meeting)

k ukončeniu riešenia projektu StruBioMol - Interreg V-A Slovensko - Rakúsko

Kedy:

28. Novembra 2022

Kde:

Ústav Molekulárnej Biológie SAV, Dúbravská cesta 21, 845 51 Bratislava ( www.imb.savba.sk)

Čas:

9.00 - 12.30

Program:

09:00 - 09:30 - Privítanie a predstavenie výsledkov projektu StruBioMol (Dr. Eva Kutejová a Dr. Vladimír Pevala)

09:30- 09:50 - Coffee break

09:50- 12:00 - Výskumné aktivity na ÚMB SAV, Max Perutz Labs a strategických partnerov

(prof. Kristina Djinović Carugo, Dr. Nina Kunová, Dr. Rostislav Škrabana a Dr. Jacob Bauer)

12:00 - 12:30 - Coffee break a Diskusia

12:30- 13:00 - Ukážka prístrojov

 

https://us02web.zoom.us/j/89270580450?pwd=aW1OSjBzdzlmcmlnQ1A1M1FEWmZHZz09

Meeting ID: 892 7058 0450
Passcode: 587758 

 

Rok 2022:

3rd StruBioMol Workshop: Macromolecular structure determination, analysis and validation

Kedy:

02.11.2022 – 03.11.2022

Kde:

Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus Vienna Biocenter 5, A-1030, Vienna

Topics:

Workshop poskytne prehľad o makromolekulárnej kryštalografii, riešení fázového problému, spresňovaní a vytváraní modelov, validácii štruktúr, analýze a databázach.

Cvičenia budú zamerané na riešenie a spresnenie štruktúry MR (1. deň popoludní, 2. deň ráno), validáciu štruktúry, analýzu a analýzu databáz.

Workshop je rozdelený do dvoch sekcií (1. deň dopoludnia s prednáškami a s praktickými cvičeniami 1. deň popoludní, 2. deň dopoludnia) a je určený pre magisterských a doktorandských študentov, postdoktorandov a ďalších výskumníkov v cezhraničnom regióne Viedeň – Bratislava. Počet účastníkov cvičení je obmedzený (20) a výber bude z prihlásených účastníkov.

Travel grants:

Pre účastníkov je k dispozícii obmedzený počet cestovných grantov a ubytovania. Žiadatelia nemusia samostatne žiadať o cestovné granty na toto podujatie, ale mali by uviesť v registračnom formulári, či si želajú, aby sa u nich uvažovalo o cestovnom grante. Výber ocenených rieši priamo organizátor, ktorý upovedomí všetkých oprávnených účastníkov.

Registrácia:

do 26.10. 2022 o 12.00 CET

 

https://forms.gle/zXfD3awmPTTwfEKV8

Kontakt:

V prípade akýchkoľvek otázok kontaktujte: admin.vbc5@univie.ac.at

Program:

Streda 2. November

 9:15 - 09:30     Welcome

 9:30 - 10:30     Overview to macromolecular crystallography 

Kristina Djinovic Carugo

10:30 - 11:30        Coffee break + Discussions

11:30 - 12:15       Solution of phase problem (focus on MR)

Vladena Bauerova

12:15 - 13:00       Refinement and model building

                        Jacob Bauer

13:00 -  14:15      Lunch + Discussions

14:30 - 16:00       Practicals 1 - Molecular replacement, model building, refinement

                        Georg Mlynek

Štvrtok 3. November

9:30 - 10:15       Structure validation and analysis and databases

                         Jacob Bauer

10:15 - 10:30     Coffee break

10:30 – 12:20    Practicals 2 - structure validation, analysis

                      Georg Mlynek

12:30 - 13:30     Lunch + Discussions

13:30 - 16:00     Practicals 2 - databases analysis

                              Vladena Bauerova

16:00             Closing remarks

 

Organizátori a rečníci:

Kristina Djinovic Carugo, Max Perutz Labs, University of Vienna

Eva Kutejová, Institute of Molecular Biology SAS, Bratislava

Vladimír Pevala, Institute of Molecular Biology SAS, Bratislava

Georg Mlynek, Max Perutz Labs, University of Vienna

Jacob Bauer, Institute of Molecular Biology SAS, Bratislava

Vladena Bauerová, Institute of Molecular Biology SAS, Bratislava

 

2nd StruBioMol Workshop: Isolation, Characterization and Crystallization of Proteins

When:

14.06.2022 – 15.06.2022

Where:

Institute of Molecular Biology, Slovak Academy of Sciences, Dubravska cesta 21, Bratislava, Slovakia

Topics:

The workshop will provide an introduction into the isolation, purification, thermal stability and crystallization of proteins. The covered techniques will be differential scanning fluorimetry (nanoDSF and Thermofluor), and protein crystallization (Manual and high-throughput techniques using Formulatrix crystallization robots). The workshop is divided into two sections (morning with lectures and afternoon with practical`s) and is intended for Masters’ and PhD students, postdocs and other researchers in the Vienna-Bratislava cross-border region. The number of attendees for practicals is limited and there will be selection from registered participants, but all registered participants can attend the morning lectures section.

The participants could bring their own protein samples for testing after prior consultation with organizers.

Travel grants:

A limited number of travel grants and accommodations are available for participants. Applicants do not need to apply separately for travel grants for this event but should indicate on the registration form if they wish to be considered for a travel grant. Selection of awardees is handled directly by the organizer who will notify all eligible participants.

Registration:

until 26.05. 2022 at 12.00 CET

 

https://docs.google.com/forms/d/e/1FAIpQLSd4T7xEx2w7F-W0nfGJenuqxbVKaf_MnIAwvkrFdig2AYdJIA/viewform

Contact:

In case of any questions, please contact: biochemiaumb@gmail.com

 

Organizers, Speakers and Tutors:

Kristina Djinovic Carugo, Max Perutz Labs, University of Vienna

Eva Kutejová, Institute of Molecular Biology SAS, Bratislava

Vladimír Pevala, Institute of Molecular Biology SAS, Bratislava

Antonio Sponga, Max Perutz Labs, University of Vienna

Pavlina Maloy Rezacova, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague

Sami Kereïche, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague

Cyril Bařinka, Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague

Jacob Bauer, Institute of Molecular Biology SAS, Bratislava

Vladena Bauerová, Institute of Molecular Biology SAS, Bratislava

Nina Kunová, Institute of Molecular Biology SAS, Bratislava

Gabriela Ondrovičová, Institute of Molecular Biology SAS, Bratislava 

 

Program:

Tuesday 14th June

 9:00 - 9:15     Welcome and Introduction

Kristina Djinovic Carugo, Eva Kutejova

9:15 - 10:15      Protein expression

Cyril Bařinka

10:15 - 11:15     Protein purification for biochemical and structural studies

Antonio Sponga

11:15 - 11:30     Coffee break

11:30 - 12:30    Protein thermal stability - differential scanning fluorimetry

Vladena Bauerová

12:30 - 13:15    Lunch + Discussions

13:15 -  15:45   Practicals on nanoDSF and thermofluor

15:45 - 16:00    Coffee break

16:00 - 18:00    Practicals on nanoDSF and thermofluor

 

Wednesday 15th June

9:00 - 10:00      Crystallisation of macromolecules

Jacob Bauer

10:00 - 11:00     X-ray crystallography in drug discovery

Pavlina Maloy Rezacova

11:00 - 11:15     Coffee break

11:15 - 12:00     Electron microscopy in protein structure determination

Sami Kereïche

12:00 - 13:00     Lunch + Discussions

13:00 -  15:00    Practicals on crystallisation

15:00 - 15:15    Coffee break

15:15 - 18:00    Practicals on crystallisation

 

Séria seminárov projektu StruBioMol

Rok 2021:

Dr. Dominika Fričová

Institute of Neuroimmunology SAS, Bratislava, Slovakia

What can we learn from Parkinson’s disease-related mutations? 

23.11.2021 o 14:00

Zoom online video presentation:

https://us02web.zoom.us/j/202574764?pwd=QjlDQ2tiU09RSUJKQkZVQUVQbWRZUT09

Abstract: 

Mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of Parkinson’s disease (PD). The identification of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and their functional association with mitochondrial quality control provided further support to this hypothesis. We have recently identified a heterozygous missense mutation in PINK1 changing glycine 411 (G411) to serine (S) that increases the risk for PD. Our studies in PD patient’s fibroblasts and derived iNeurons carrying heterozygous PINK1 p.G411S mutation revealed aberrant auto-phosphorylation of PINK1 p.G411S and significant reduction of PINK1 kinase activity. We uncovered a partial loss-of-function as well as a dominant-negative effect of the PINK1 p.G411S due to its interaction with WT PINK1. Subsequent impairment in cytoprotective functions of the PINK1/Parkin-mediated mitochondrial quality control then causes later manifestation of the disease in heterozygous p.G411S mutation carriers than homozygous loss-of-function mutations in PD cases. In order to analyze the molecular mechanisms of p.G411S mutation-mediated pathobiology in greater detail we employed CRISPR/Cas9 technique and introduced p.G411S mutation in HEK293T cells. As a control for our experiments, we introduced in the same genetic background a point mutation which doesn’t allow aberrant PINK1 phosphorylation - PINK1 G411 to alanine (A). Our experiments indicate that aberrant phosphorylation of S411, alters substrate binding and reduces the activity of PINK1 towards Ub and Parkin phosphorylation. Surprisingly, introduction of non-phosphorylatable residue A411 dramatically increased the activity of PINK1 towards these substrates. Our findings are supported by structural modeling and dynamics simulations that suggest higher receptivity of PINK1 A411 across different PINK1 substrates. Importantly, the increase of PINK1 A411 activity translates to higher mitochondrial turnover after mitochondrial damage induction with potential cytoprotective impact.

 

Prof. Tony Wilkinson

Head of York Structural Biology Laboratory, Department of Chemistry, University of York, UK

Systémy posttranslačných modifikácií ako ciele inhibície v liečbe Leishmaniózy

04.05.2021 o 14:00

 ZOOM Online videoprezentácia:

https://us02web.zoom.us/j/202574764?pwd=QjlDQ2tiU09RSUJKQkZVQUVQbWRZUT09

Abstrakt: Leishmaniases are a group of neglected tropical diseases caused by protozoan Leishmania parasites, which are transmitted by sand flies. There are three main forms of the disease with cutaneous leishmaniasis (CL) the most common and visceral leishmaniasis (VL) the most severe and usually fatal if untreated. Up to one billion people live in areas of the world where leishmania is endemic leading to over 1 million new CL cases and 30,000 new VL cases each year. There is no vaccine available so chemotherapy is the principal method of intervention. Current drugs suffer from various drawbacks including toxic side effects, lack of oral formulation, prolonged treatment times, high costs of treatment and the emergence of drug resistance. As a result, there is a pressing need to discover and develop new drugs for the treatment of leishmaniasis. With this in mind, we have been carrying out drug target validation of post-translational modification (PTM) enzymes of Leishmania. PTM systems have proved fertile territory for therapeutic intervention in human disease with many current therapies targeting PTM components. We belong to a Neglected Tropical Diseases Network involving groups in Asia and South America that is using gene knock-out/knock-down technologies to identify essential PTM genes in Leishmania species. We are especially interested in genes required for parasite differentiation from the promastigote form, which is transmitted by the sand fly, to the amastigote form that establishes infection and causes human disease. Targets identified and characterised in studies of the parasite ubiquitination/deubiquitination system will be discussed (1).

The talk will then describe an in-depth study of N-myristoyltransferase (NMT) an enzyme which catalyses the co-translational attachment of a C14 fatty acid to the amino terminal glycine residue of a subset of proteins. NMT is an essential enzyme in L. donovani and a promising target for drug discovery. In a collaborative study, we carried out high-throughput screens for inhibitors (2) and followed this is up with a combination of Medicinal Chemistry, Structural Biology and Parasitology to develop several compound series into potent and specific inhibitors (3, 4). As part of this work, inhibitors of the human host NMT were discovered, which showed potential for the treatment of diseases caused by picornaviruses including the common cold.

1. Burge RJ, Damianou A, Wilkinson AJ, Rodenko B, & Mottram JC (2020) Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex. PLoS Pathog 16(10):e1008784.
2. Brannigan J, et al. (2014) Diverse modes of binding in structures of Leishmania major N-myristoyltransferase with selective inhibitors. IUCr Journal 1:250-260.
3. Bell AS, et al. (2020) Novel Thienopyrimidine Inhibitors of Leishmania N-Myristoyltransferase with On-Target Activity in Intracellular Amastigotes. J Med Chem 63(14):7740-7765.
4. Mousnier A, et al. (2018) Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nat Chem 10(6):599-606.
 

Dr. Jacob BAUER

Ústav molekulárnej biológie SAV, Dúbravská cesta 21, Bratislava, Slovakia

Analýza v normálnom režime a jej aplikácia na štúdie štruktúry proteínov

14.01.2021 o 14:00

Abstrakt: Normal Mode Analysis (NMA) is a computational technique that can be used to calculate the flexible states available to a protein from a given equilibrium conformation. It produces results comparable to those from molecular dynamics simulation combined with principal components analysis but at a fraction of the computational cost. Although it has been used for certain applications in protein crystallography for many years, it is still uncommon to find it a part of the analysis step in a protein crystal structure study. Here, I will briefly describe the theory and most common applications of NMA. I will illustrate some of its strengths and limitations using a case study from the literature, and will discuss a potential application to single-molecule optical tweezers experiments 

ZOOM Online videoprezentácia: https://zoom.us/j/91905230005?pwd=anZ0aXlJandMTEpEcCtQUzJoMmxtZz09

Meeting-ID: 919 0523 0005

Kenncode: 997466

Host: Kristina Djinovic-Carugo